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Abstract
Estrogen may be involved in the development of prostate cancer. The association between genetic polymorphisms of
estrogen receptors a (ESR1) and b (ESR2) and prostate cancer risk was examined in a nested case-control study in
Washington County, Maryland. Incident prostate cancer cases (n=269) were matched to one or two controls (n=440) by
age, sex, race, and date of blood donation. Associations between estrogen receptor genotypes or dietary intake and the
development of prostate cancer were examined in conditional logistic regression models. Results from this study showed
that six single base-pair polymorphisms (SNPs) of ESR1 (rs1801132, rs2077647, rs746432, rs2273206, rs851982, rs2228480)
and four SNPs of ESR2 (rs4986938, rs928554, rs8018687, rs number not available for ESR2 5696 bp 39 of STP A.G) were not
significantly associated with prostate cancer risk, either by allelic or genotypic frequencies. However, an interactive
association with BMI was observed in the relationship between prostate cancer risk and genotypes of ESR2 38 bp 39 of STP
G.A (rs4986938) (p=0.031). An interaction between intake level of phytoestrogen and genotypes of ESR1 Ex1-192G.C
(rs746432) and between intake level of phytoestrogen and genotypes of ESR1 Ex8+229G.A (rs2228480) and risk of prostate
cancer was observed (p=0.0009 and p=0.044, respectively). In conclusion, selected genetic polymorphisms of ESR1 and
ESR2, overall, were not associated with prostate cancer risk. However, a variation in risk by BMI and phytoestrogen intake
was implicated.
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Introduction
The development of prostate cancer may be hormone-
dependent [1,2]. For example, androgens are important for
normal and hyperplastic prostate growth. Both testosterone and
dihydrotestosterone (DHT) induced prostatic adenocarcinoma in
rat models [3]. Anti-androgen therapy or orchiectomy has been
used to treat metastatic prostate cancer [4]. Estrogen as well as
androgen may play an important role in the carcinogenesis of
prostate cells [5]. It was initially thought that estrogens mediate
their action through estrogen receptor a (ESR1). Estrogen
receptor b (ESR2) was later identified to be involved in the
process [6,7]. Although these two receptors share 47% structural
similarities, they can be differentiated by their physiological
properties [6,8]. While ESR1 is mainly localized in the prostatic
stroma [9], ESR2 is mostly located in the prostatic epithelium
[10]. ESR1 plays an essential role in prostate development [11]
and is found to be related to estrogen-induced prostatic squamous
metaplasia [12]. Also, its expression at tumor level negatively
correlates with prostate cancer survival [13]. On the other hand,
ESR2 is thought to be an important regulator of prostate function
[14], especially as a potential ‘‘brake’’ to androgen-driven
proliferation [13].
Several studies have suggested a relationship between these two
receptors and prostate cancer [15–21]. For example, exposure to
high levels of estrogen in uteri may lead to smaller adult prostates
that are poorly sensitive to androgen for the development of
hyperplasia, inflammation and dysplasia [16]. This genetic
imprinting is found to be mediated by ESR1 [16]. Other studies
have consistently found that ESR2 is expressed in metastatic
prostate cancer cells [17–19]. Accordingly, phytoestrogens,
chemicals produced by plants that mimic estrogen effects, may
act like ESR2 agonist. It has been hypothesized that phytoestrogen
may be protective against prostate cancer [20,21].
Genetic polymorphisms of the ESR1 and ESR2 have been
reported to be associated with prostate cancer risk [22–34].
However, no biological functional studies have been published to
support the epidemiologic findings, and analyses of gene-
environment interactions were rarely performed. Identifying
the environmental factors that may modify the relationship
between genetic polymorphisms and disease risk may provide a
clue to possible functions of the genetic polymorphisms or to the
locations of functional SNPs. Body mass index (BMI) may be a
proxy indicator for the relative amount of body fat, which is a
major source of estrogen production in men [35]. Availability of
estrogen in the body may affect the sensitivity of estrogen
receptors, possibly leading to a different risk profile for prostate
carcinogenesis. On the other hand, phytoestrogen, rich in
legumes, may stimulate or modulate estrogen receptors, partic-
ularly for ESR2 [36].
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associations between selective polymorphisms of ESR 1, ESR2
genes and the risk of developing prostate cancer in a community-
based cohort in Washington County, Maryland. Exploratory
analyses examined how the ESR1 and ESR2 SNPs of interest
modified the association between BMI/phytoestrogen and pros-
tate cancer risk and also how BMI and phytoestrogen altered the
association between the ESR1 and ESR2 SNPs of interest and
prostate cancer risk.
Materials and Methods
Study population
CLUE II was a slogan of the second research campaign, ‘‘Give
us a CLUE to cancer and Heart Disease’’, conducted in
Washington County, Maryland in 1989. The participants were
10,456 men and 14,625 women (total of 25,081). Approximately
30% of the Washington County adult population participated.
Mobile office trailers were utilized to collect specimen. 20 ml of
blood from each participant was put into 20 ml vacutainer. In
addition to plasma aliquots, white blood cells and a sample with a
vitamin C preservative were stored at 270uC. Buffy coats from the
samples were used as a source of the genotyping analysis.
Study participants provided data on education, cigarette
smoking (never, former, current), height, weight, medication use,
and vitamin use in the year prior to questionnaire administration.
They also filled out a brief food frequency questionnaire [37] that
included questions about the serving size and frequency of intake
of 61 food items. The annual loss-to-follow-up in the cohort was
less than 1 percent.
A written informed consent to the participation in the research
campaign was obtained from each participant at the time of blood
donation. This study was approved by the institutional review
board of the Johns Hopkins Bloomberg School of Public Health.
Case ascertainment and control selection
Prostate cancer incident cases (International Classification of
Diseases, 9th revision, code 185) were identified through linkage to
the Washington County Cancer Registry and since 1992, also to
the Maryland State Cancer Registry. All cases were confirmed
pathologically (n=269). Stages and grades were described
according to American Joint Committee on Cancer/Tumor Node
Metastasis (TNM) system and Gleason’s Score system, respective-
ly.
Cases were defined as participants who developed primary
prostate cancer during the follow up period from 1989 to 2002.
Each prostate cancer case was individually matched with one or
two controls on age (61 year), gender, ethnicity, and date of blood
donation. One-to-one and one-to-two matching was done for 36%
and 64%, respectively, of the cases. Each control was selected from
the CLUE II cohort, not known to have cancer except for basal or
squamous cell skin cancer and not known to have died, at the time
when the corresponding case was diagnosed.
Genotyping
Heparinized blood samples were centrifuged at 1500 g for 30
minutes at room temperature within 6 hours of collection. Then
they were separated into plasma, buffy coat, and red blood cells
and were frozen at 270uC within 24 hours of collection. Genetic
polymorphisms of estrogen receptor a (ESR1) and estrogen
receptor b (ESR2) were determined on DNA samples extracted
from the preserved participants’ buffy coat specimens. The buffy
coat remained frozen till DNA extraction was done. The alkaline
lysis method was used for the DNA extraction procedure. All
genotypings were carried out using TaqManH assays (Applied
Biosystems, Foster city, CA, USA). Laboratory researchers
handling samples were masked to disease status.
Candidate single nucleotide polymorphisms (SNPs) were chosen
based on the following criteria: (a) the allele frequency of over five
percent in published literature or databases, recommended by the
National Cancer Institute [38], (b) validated allele substitutions,
and/or (c) functional changes linked with allele substitution
reported in the literature.
For describing SNP sequence variations, we adapted the
recommendation from a Nomenclature Working Group [39].
Among the ESR1 SNPs, four SNPs including Ex4-122C.G,
Ex1+392T.C, Ex1-192G.C, and Ex8+229G.A were in the
coding region. The rest of the ESR1 SNPs were either in the non-
coding region prior to ATG translation initiating codon
(-104062C.T), or in the intron 6 region (IVS6+52G.T). All of
the ESR2 SNPs were in the non-coding region after the translation
terminating codon (38 bp 39 of STP G.A, 5659 bp 39 of STP
A.G, 5696 bp 39 of STP A.G, 5772 bp 39 of STP A.G). Ten
selected SNPs were genotyped in both cases and controls. Among
cases, 13.1% (35/269) were missing any one genotype and among
controls, 10.5% (46/440). Average missing rate for any one
genotype was around 18%.(I have erased the accuracy part.)
Statistical Analysis
Baseline characteristics between cases and controls were
compared by conditional logistic regression models for categorical
variables (Table 1). Based on self-reported height and weight at the
time of blood donation, we calculated BMI as kilogram per square
meter. Family history was identified by self report on the prostate
cancer history of grandfathers, fathers and brothers. Dietary intake
of fat, energy, phytoestrogen, and calcium was estimated by
summing the product of the frequency of consumption of each
food, the reported serving size, and the energy or nutrient content
per serving. Total phytoestrogen intake was computed based on
legume consumption. Isoflavone (phytoestrogen) contents were
estimated for beans (pinto, lima, kidney, and other beans, possibly
including soy), peas, and peanuts using USDA-Iowa State
University Database on the Isoflavone Content of Foods, 1999
[40]. All quartile cut-offs used were based on the data in the
control group. High/low phytoestrogen intake cut-off was the
median level of intake in the control group. To deal with missing
data for dietary (average of 30% missing) in calculating the total
isoflavone intake, imputation analysis was performed, inserting
zero or median in place of missing data, both of which did not
affect the overall results.
Association between estrogen receptor genotypes and the
development of prostate cancer was examined in conditional
logistic regression analyses. Odds ratios and the corresponding
95% confidence intervals were derived from three different genetic
effect models, including dominant, recessive and additive models.
Additionally, analyses were stratified by cancer stage and grade.
Gene-environment interaction associations of BMI or dietary
phytoestrogen (isoflavone) intake on the relationship between
prostate cancer risk and estrogen receptor gene genotypes were
assessed by both stratification analyses and the likelihood ratio test
(LRT) that compared the conditional logistic regression models
with and without interaction terms. Associations between ESR1
and ESR2 genotypes and prostate cancer risk were evaluated in
strata of three BMI categories and separately, strata of high/low
phytoestrogen intake, by unconditional logistic regression with
adjustment for age and race. The same method was used to assess
the associations between BMI or dietary phytoestrogen intake and
prostate cancer risk in strata of estrogen receptor genotypes, with
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Characteristics case subjects (n=269) control subjects (n=440) matched odds ratio 95% confidence interval
Age, y, mean(SE) 64.1( 9.0) 64.7(8.7)
Race, Black, n, (%) 6(2.23) 11(2.50)
Education level, y, %
,12 27.1 34.1 1.00
=12 42.8 37.3 1.38 0.94, 2.02
.12 30.1 28.6 1.25 0.84,1.84
Cigarette smoking, %
never 39.8 39.3 1.00
former 51.7 50.2 1.02 1.75,1.41
current 8.5 10.5 0.83 0.44,1.40
BMI at baseline, kg/m
2,%
,24.9 33.1 30.2 1
25–29.9 52.4 55.9 0.84 0.59,1.19
.=30 14.5 13.9 0.95 0.57,1.57
BMI at age 21, kg/m
2,%
,24.9 80.9 78.2 1
25–29.9 16.1 19.8 0.79 0.53,1.18
.=30 3.0 2.1 1.19 0.42,3.34
Vitamin supplement use, %
multivitamin regular use* 23.6 20.2 1.11 0.71,1.73
ever vitamin C use
{ 37.6 34.6 1.04 0.75,1.46
ever vitamin D use
{ 25.2 21.6 1.17 0.81,1.69
ever vitamin E use
{ 34.8 33.1 1.01 0.72,1.41
Family history
{,%
no 58.7 63.4 1.00
yes 8.6 5.5 1.69 0.82,3.48
missing 32.7 31.1
Dietary intake of fat, %
1st quartile
P 23.4 22.7 1.00
2nd quartile
P 18.6 23.0 0.79 0.50,1.27
3rd quartile
P 24.5 22.7 0.93 0.58,1.50
4th quartile
P 26.4 23.0 1.08 0.68,1.70
missing 7.1 8.6
Dietary intake of total calories, %
1st quartile
P 20.1 22.7 1.00
2nd quartile
P 25.3 23.0 1.22 0.77,1.93
3rd quartile
P 21.6 22.7 1.01 0.63,1.63
4th quartile
P 26.0 23.0 1.25 0.78,1.20
missing 7.1 8.6
Dietary intake of calcium, %
1st quartile
P 20.1 22.7 1.00
2nd quartile
P 24.9 23.0 1.11 0.70,1.78
3rd quartile
P 26.0 22.7 1.22 0.78,1.92
3rd quartile
P 21.9 23.0 1.08 0.66,1.75
missing 7.1 8.6
Dietary intake of phytoestrogen, %
1st quartile
P 19.7 17.5 1.00
2nd quartile
P 17.8 17.3 0.77 0.43,1.39
3rd quartile
P 13.4 17.3 0.58 0.31,1.09
4th quartile
P 21.2 17.3 0.97 0.55,1.71
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intake, age, and race. For BMI, test for trend was performed on
the median values in each three categories. For genotypes, the
additive model was assumed in the tests for trend. All p-values
were derived from two-sided test and were considered to be
statistically significant if less than 0.05. All statistical analyses were
performed using STATA Statistical Software, 9.0 (Stata Corpo-
ration, College Station, TX, 2005).
Results
Cases and controls were comparable with respect to age, race,
education, history of cigarette smoking, vitamin use, and dietary
intakes of fat, total calories, phytoestrogen, and calcium (Table 1).
Among the 188 cases whose disease stages were determined, 129
had localized disease, defined as TNM stage 0, 1 or 2, and 59 had
advanced disease, defined as TNM stage 3 or 4 (Table 1). Hardy-
Weinberg equilibrium was tested for Caucasians in controls, who
were 263 (94%) and 429 (89%) in each group. All the SNPs were
in Hardy-Weinberg equilibrium except for ESR2 5659 bp 39 of
STP A.G among cases and ESR1 IVS6+52G.T, ESR1 -
104062C.T, 5659 bp 39 of STP A.G among controls (Table
S1). Observed major allele frequencies of ESR SNPs from the
CLUE cohort were compared with SNP500 or dbSNP data if
available, separately for Caucasians and African Americans.
Among the eight SNPs compared, no statistically significant
difference was found with the exception of ESR1 Ex8+229G.A
for Caucasians (Table S2).
Table 2 presents odd ratio estimates of prostate cancer risk for
each genotype of estrogen receptor gene SNP. In dominant,
recessive, and additive models, no statistically significant associa-
tion was found between the SNPs and prostate cancer risk. In
addition, no significant trend was found in the number of alleles
with respect to prostate cancer risk. Of all ten SNPs, only ESR1
Ex4-122C.G was consistently associated with increased prostate
cancer risk across all subgroups defined by stages and grades of the
cancer (Table 2). However, none of the results were statistically
significant. Among advanced prostate cancer cases, for ESR1, C
allele in Ex1+392T.C was associated with a statistically
significant decreased risk of prostate cancer. The T allele in
IVS6+52G.T was associated with an increased risk of prostate
cancer but the trend in risk with burden of T alleles was not
statisticially significant. For ESR2, A allele in 38 bp 39 of STP
G.A and A allele in 5659 bp 39 of STP A.G were associated
with an increased risk of advanced prostate cancer but association
were not statistically significant. (Table 2).
Among the the group with low intake of phytoestrogen, men
who had the variant homozygote G/G genotype in ESR1 Ex4-
122C.G had a 5-fold increase in the odds of developing prostate
cancer when compared with wild type homozygote C/C genotype
(P=0.02, p-value for trend=0.04) (Table 3). In contrast, men
who had a variant homozygote C/C genotype in ESR1
Ex1+392T.C and G/C, C/C genotype in ESR1 Ex1-192G.C
had a decrease in the odds of developing prostate cancer by 63%
(P=0.017, p-value for trend=0.015) and 75% (P=0.004)
compared to wild type homozygote T/T and G/G genotype,
respectively (Table 3).
Overall, there was little evidence to suggest an interaction
between genotypes and BMI, except that obese men (BMI$30 kg/
m
2) with heterozygote G/A genotype in ESR2 38 bp 39 of STP
G.A had a 72% lower risk of prostate cancer (P=0.026), and that
more A alleles in ESR2 5659 bp 39 of STP G.A were associated
withincreased prostate cancerrisk inmen withBMI,25 kg/m
2 (p-
value for trend=0.053). Similar results were observed when BMI of
27 or 27 kg/m
2 was used as the cutoff for grouping (data not
shown).
Characteristics case subjects (n=269) control subjects (n=440) matched odds ratio 95% confidence interval
missing 27.9 30.7
Stage of disease at diagnosis, %
0 1.1
1 14.9
2 32.0
3 18.2
4 3.7
missing 30.1
Grade of disease at diagnosis
1,%
1 7.8
2 64.7
3 7.4
missing 20.1
Case/control, %
one/one 36.0
one/two 64.0
*regular users compared with nonusers and non-regular users among responder of the questionnaire.
{ever-users compared with nonusers among responders of the questionnaire.
{prostate cancer of grandfather, father, and brothers.
1Grade: 1(Gleason score 2–4, well differentiated), 2(Gleason score 5–7, moderately differentiated), 3(Gleason score 8–10, poorly differentiated).
PAll quartiles are derived from controls: 1) total caloric intake (n=652) quartile cut off: 1107.8, 1438.4, 1861.8 Cal/d. 2) fat intake (n=652) quartile cutoff: 42.1, 59.0, 78.2
Cal/d. 3) calcium intake (n=652) quartile cutoff: 424.0, 616.4, 878.7 mg/d 4) phytoestrogen intake (n=499) quartile cut off: 1.35, 2.71, 4.14 mg/mo.
doi:10.1371/journal.pone.0006523.t001
Table 1. Cont.
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PLoS ONE | www.plosone.org 6 August 2009 | Volume 4 | Issue 8 | e6523Table 3. Estrogen receptor gene polymorphisms and prostate cancer risk according to BMI and habitual dietary intake of
Phytoestrogen.
SNP Odds Ratio (95%CI)
Overall Phytoestrogen* BMI
{
(case/control) Low (101/153) High (93/152) ,25 (89/133) 25–30 (141/246) (30 (39/61)
ESR1 Ex4-122C.G
C/C 1.00 1.00 1.00 1.00 1.00 1.00
C/G 1.08 (0.75,1.55) 1.32 (0.72,2.42) 1.19 (0.66,2.14) 0.71 (.38,1.35) 1.40 (0.86,2.26) 2.08 (0.71,6.05)
G/G 1.73 (0.78,3.85) 5.16 (1.24,21.51) 1.85 (0.51,6.80) 2.48 (0.59,10.42) 1.68 (0.36,7.76) 1.95 (0.45,8.44)
P trend 0.041 0.338 0.946 0.151 0.197
ESR1 Ex1+392T.C
T/T 1.00 1.00 1.00 1.00 1.00 1.00
T/C 0.92 (0.60,1.41) 0.61 (0.32,1.18) 1.12 (0.56,2.25) 1.05 (0.51,2.17) 1.10 (0.64,1.89) 0.67 (0.23,1.91)
C/C 0.87 (0.54,1.41) 0.37 (0.17,0.84) 1.38 (0.63,3.06) 0.96 (0.44,2.08) 0.95 (0.49,1.85) 0.39 (0.09,1.03)
P trend 0.015 0.421 0.914 0.924 0.196
ESR1 Ex1-192G.C
G/G 1.00 1.00 1.00 1.00 1.00 1.00
G/C,C/C 0.96 (0.60.1.55) 0.25 (0.10,0.64) 1.32 (0.64,2.71) 0.65 (0.28,1.50) 1.16 (0.65,2.07) 0.76 (0.21,2.76)
P trend 0.004 0.45 0.315 0.61 0.674
ESR1 IVS6+52G.T
G/G 1.00 1.00 1.00 1.00 1.00 1.00
G/T 1.19 (0.79,1.78) 1.20 (0.57,2.51) 1.61 (0.84,3.07) 1.88 (0.85,4.16) 1.12 (0.64,1.98) 0.65 (0.22,1.94)
T/T 1.41 (0.44,4.49) 0.93 (0.16,5.47) 5.59 (0.37,84.23) 0.68 7.98 (0.73, 86.21)
{NA
P trend 0.755 0.07 0.408 0.24 0.239
ESR1 -104062C.T
C/C 1.00 1.00 1.00 1.00 1.00 1.00
C/T 1.09 (0.71,1.67) 0.84 (0.43,1.66) 1.05 (0.50,2.18) 1.00 (0.49,2.03) 1.42 (0.82,2.48) 0.79 (0.24,2.57)
T/T 0.9 (0.33,2.47) 0.67 (0.11,3.87) 1.70 (0.41,7.09) 0.76 (0.17,3.33) 1.63 (0.42,6.31)
{NA
P trend 0.525 0.565 0.81 0.178 0.205
ESR1 Ex8+229G.A
G/G 1.00 1.00 1.00 1.00 1.00 1.00
G/A 1.03(0.70,1.53) 1.06 (0.56,2.01) 0.58 (0.31,1.08) 0.87 (0.46,1.67) 1.24 (0.74,2.08) 0.71 (0.26,1.93)
A/A 1.17(0.70,1.96) 2.05 (0.92,4.58) 0.56 (0.24,1.29) 1.26 (0.54,2.92) 1.28 (0.65,2.53) 0.75 (0.18.3.15)
P trend 0.115 0.101 0.146 0.418 0.585
ESR2 38 bp 39 of STP G.A
G/G 1.00 1.00 1.00 1.00 1.00 1.00
G/A 0.95 (0.64,1.41) 1.10 (0.59,2.06) 0.92 (0.50,1.68) 1.24 (0.65,2.39) 1.03 (0.62,1.71) 0.28 (0.09,0.86)
A/A 0.98 (0.57,1.70) 1.42 (0.60,3.37) 1.07 (0.46,2.51) 1.35 (0.55,3.33) 0.92 (0.44,1.90) 1.17 (0.29,4.74)
P trend 0.455 0.986 0.455 0.875 0.443
ESR2 5659 bp 39 of STP A.G
G/G 1.00 1.00 1.00 1.00 1.00 1.00
G/A 1.21 (0.71,2.07) 1.16 (0.51,2.63) 0.75 (0.32,1.78) 1.60 (0.67,3.84) 1.39 (0.65,3.00) 0.58 (0.17,1.92)
A/A 1.16 (0.66,2.03) 1.14 (0.47,2.75) 1.01 (0.39,2.62) 2.54 (0.96,6.72) 1.12 (0.50,2.54) 0.58 (0.16,2.10)
P trend 0.816 0.778 0.053 0.906 0.438
ESR2 5696 bp 39 of STP A.G
A/A 1.00 1.00 1.00 1.00 1.00 1.00
A/G,G/G 1.04 (0.61,1.75) 1.21 (0.58,2.55) 0.51 (0.19,1.37) 1.2 (0.51,2.85) 1.07 (0.57,2.02) 0.82 (0.22,3.06)
P trend 0.613 0.183 0.676 0.835 0.773
ESR2 5772 bp 39 of STP A.G
A/A 1.00 1.00 1.00 1.00 1.00 1.00
A/G,G/G 1.07 (0.64,1.79) 0.63 (0.23,1.72) 1.23 (0.59,2.56) 1.03 (0.43,2.50) 1.19 (0.61,2.33) 0.98 (0.26,3.67)
Prostate Cancer Polymorphism
PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6523In men with a T/T genotype in ESR1 Ex1+392T.C, A/A
genotype in ESR1 Ex8+229G.A, and A/G or G/G genotype in
ESR2 5696 bp 39 of STP A.G (Table 4), high phytoestrogen
group had a 58% (P=0.048), 64% (P=0.047) and 80%
(P=0.034) lower risk of developing prostate cancer, respectively.
In contrast, in men with G/C, C/C genotype in ESR1 Ex1-
192G.C, the high phytoestrogen group had 3.3 times the odds of
developing prostate cancer compared with the low phytoestrogen
group (P=0.034).
A higher BMI was not associated with prostate cancer risk [OR
(95% CI)=0.84 (0.59, 1.19) in over-weight men, and OR (95%
CI)=0.95 (0.57, 1.57) in obese men]. In men with certain SNPs, a
trend in reductions in prostate cancer was noted with increased
BMI. In particular, for men with G/A, G/G genotype in ESR2
38 bp 39 of STP G.A, having a BMI of $30 kg/m
2 was
associated with a reduced the odds of developing prostate cancer
by 57% compared to having a BMI of ,25 kg/m
2 (p-value for
trend=0.01) (Table 4).
An interaction association by BMI on the relationship between
prostate cancer risk and ESR genotypes was suggested for ESR2
38 bp 39 of STP G.A (P=0.031). Interaction association by
intake level of phytoestrogen on the relationship between prostate
cancer risk and ESR genotypes was suggested for both ESR1 Ex1-
192G.C (P=0.0009) and ESR1 Ex8+229G.A (P=0.044).
Discussion
In this study, there was no overall association between prostate
cancer risk and genotypic and allelic frequencies of ESR1 and
ESR2 SNPs. Among those who were diagnosed with advanced
prostate cancer, associations between prostate cancer risk and
genotypes were suggestive for four SNPs: ESR1 Ex1+392T.C,
ESR1 IVS6+52G.T, ESR2 38 bp 39 of STP G.A and ESR2
5659 bp 39 of STP A.G. Exploratory analyses suggested potential
interactions between environmental exposure (BMI/phytoestro-
gen), and polymorphic variations in estrogen receptor genes
resulting in differential prostate cancer risks.
With respect to ESR1, eight studies have addressed the same
question as the present study did. In a Japanese study, codon
10(TRC) was associated with a 2-fold increased risk for prostate
cancer (OR=2.03, 95% CI: 1.17–3.53) [22]. Another study, also
in Japan, reported a significant association of the T/T genotype of
the PvuII site in the ESR1 (OR=3.44; 95% CI:1.97–5.99) [23].
This finding was confirmed by an UK study (OR=4.65; 95%
CI:1.60–13.49) [24] and an Indian study (OR=2.15, 95%
CI:1.06–4.37) [25]. In a study in the U.S., a possible association
was found between prostate cancer risk and ESR1 intronic
restriction site, XbaI and PuII, but the association was not
statistically significant. [26]. Another study found an association
between the AG genotype, as well as presence of the G allele
within the XbaI ESR1 SNP and prostate cancer risk, but no
association between the PvuII SNP and prostate cancer in black
men [27]. In a French study, variant of the GGGA polymorphism
from the ESR1 was associated with an increased risk of developing
prostate cancer [28,29]. Recently, Cunningham et al. have
reported null association between ESR1 SNPs: IVS1-397,
g34288C/T (rs2234693), IVS1-351, g3433A/G (rs9340799),
ESR1 TA repeat polymorphism and prostate risk [30]. Converse-
ly, McIntyre et al. observed that prostate cancer risk was greater
with ESR1 (TA)24 and (TA)25 carriers [31]. However, none of the
SNPs mentioned above overlapped with the SNPs examined in
this study.
Consistent with our study findings, Cancel-Tassin et al. (2003)
reported no association between prostate cancer risk and
genotypes of ESR1 Ex1+392T.C and ESR2 Ex8+229G.A
[28]. In that study, ESR1 Ex4-122C.G was shown to be
associated with breast cancer [41] and the progression of prostate
cancer [42], which is commensurate with our findings of higher
risk for being diagnosed to have advanced disease. However, the
authors did not find an association with prostate cancer incidence.
In addition, Medeiros et al. (2003) reported a link of ESR1 Ex4-
122C.G to unfavorable outcome parameters such as high
pathologic grade and clinical stage [42], a finding consistent with
ours that clinical stage was associated with the genotypes of ESR1
Ex4-122C.G (p value from chi-square test=0.05).
Four previous studies have been published regarding association
between polymorphisms in ESR2 and prostate cancer risk. One
study was conducted in China, and the genotype and allele
frequency of rs3829768 (A/G) and rs1271572 (C/A) in the
upstream region of proximal promoter was significantly lower in
prostate cancer cases than controls (P,0.01) [32]. The other study
was conducted in Sweden with findings that genotype and allele
frequency of rs2987983 (T/C) in the promoter region was
associated with prostate cancer risk [33], and that the protective
effect of phytoestrogen on prostate cancer was significant among
men with carriers homozygous for the wild type allele (TT) of the
same SNP [34]. Of recent, two studies have reported null
association between ESR2 CA repeat polymorphism and prostate
cancer [30,31]. In a French study, additional 14 ESR2 SNPs were
noted to have no association with prostate cancer risk [29].
Consistent with our findings, Cunningham et al. [30] observed
null association between ESR2 39togene, g.49888G/A
(rs4986938). Except for this one study [30], previous studies have
not reported on the SNPs included in the present study. For
example, while a study in Sweden investigated four SNPs in the
promoter region and introns of ESR2, the SNPs examined in this
study were in the downstream non-coding region of ESR2 [33,34].
SNP Odds Ratio (95%CI)
Overall Phytoestrogen* BMI
{
(case/control) Low (101/153) High (93/152) ,25 (89/133) 25–30 (141/246) (30 (39/61)
P trend 0.369 0.589 0.943 0.611 0.974
*Phytoestrogen: low (n=254), high (n=245); ‘Low’ and ‘High’ is defined as below and above the median total phytoestrogen intake of controls, 2.71 mg/mo. Missing
values were excluded from the analysis.
{BMI: ,25 (n=222 ), 25–30 (n=387), $30 (n=100 ).
{NA: no applicable estimate due to small sample number.
All odds ratios are adjusted for age and race.
doi:10.1371/journal.pone.0006523.t003
Table 3. Cont.
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PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6523A few epidemiological studies supported the hypothesis of a
protective association between phytoestrogen (isoflavone) intake
and prostate and breast cancers [20,21]. Our study, however, did
not show overall protective association of phytoestrogen intake for
prostate cancer but did find a suggested interaction with two ESR1
SNPs (rs746432, rs2228480). Swedish study has identified
rs2987983 in the promoter region of ESR2, which was not
included in our study, as a potential effect modifier in the
relationship between the intake of phytoestrogen and the risk of
prostate cancer [34]. Two aspects of the data on phytoestrogen
intake should be noted. First, missing data may have compromised
the validity for assessing the association between phytoestrogen
consumption and prostate cancer risk. In CLUE II, the food
frequency questionnaire did not include soy beans or soy products
such as soy milk and tofu. However, these are not expected to be a
predominant source of phytoestrogens in this population.
Furthermore, at the time of the CLUE study enrollment in
1989, soy products were not prevalent in the American diet. This
study estimated the amount of phytoestrogen (isoflavone) intake by
summing up the intakes of three legume items (beans, peas,
peanuts), which were the predominant sources of phytoestrogen in
the American diet. In summing the intakes of legume items, since
Table 4. The effect of phytoestrogen* and BMI on the risk of prostate cancer by the genotypes of estrogen receptor gene SNPs.
SNP Odds Ratio (95%CI)
(case/control) Phytoestrogen* BMI
{
Low (101/153) High (93/152) ,25 (89/133) 25–30 (141/246) $30 (39/61) P trend
Overall 1.00 0.86 (0.55,1.33) 1.00 0.84 (0.59,1.19) 0.95 (0.57,1.57)
ESR1 Ex4-122C.G
C/C 1.00 0.89 (0.51,1.55) 1.00 0.55 (0.34,0.89) 0.57 (0.28,1.15) 0.036
C/G 1.00 0.85 (0.42,1.71) 1.00 1.15 (0.61,2.17) 1.52 (0.56,4.12) 0.426
G/G 1.00 0.91 (0.06,14.34) 1.00 0.39 (0.05,3.03) 0.43 (0.06,2.96) 0.393
ESR1 Ex1+392T.C
T/T 1.00 0.42 (0.18,0.99) 1.00 0.65 (0.32,1.33) 1.10 (0.41,2.93) 0.851
T/C, C/C 1.00 1.23 (0.74,2.04) 1.00 0.63 (0.41,0.98) 0.56 (0.28,1.08) 0.036
ESR1 Ex1-192G.C
G/G 1.00 0.64 (0.39,1.02) 1.00 0.60 (0.40,0.91) 0.82 (0.45,1.47) 0.166
G/C,C/C* 1.00 3.30 (1.09,9.96) 1.00 0.98 (0.38,2.54) 0.79 (0.19,3.24) 0.781
ESR1 IVS6+52G.T
G/G 1.00 0.82 (0.51,1.32) 1.00 0.70 (0.46,1.07) 0.93 (0.51,1.72) 0.431
G/T 1.00 1.38 (0.53,3.55) 1.00 0.39 (0.16,0.95) 0.36 (0.11,1.17) 0.059
T/T 1.00
{NA 1.00 2.62 (0.11,64.84)
{NA 0.864
ESR1 -104062C.T
C/C 1.00 0.79 (0.47,1.33) 1.00 0.59 (0.37,0.93) 0.85 (0.43,1.67) 0.237
C/T, T/T 1.00 0.91 (0.38,2.19) 1.00 0.86 (0.41,1.79) 0.50 (0.16,1.56) 0.271
ESR1 Ex8+229G.A
G/G 1.00 1.99 (0.96,4.13) 1.00 0.58 (0.31,1.09) 0.93 (0.39,2.25) 0.479
G/A 1.00 0.87 (0.47,1.63) 1.00 0.82 (0.47,1.42) 0.68 (0.31,1.50) 0.318
A/A 1.00 0.34 (0.12,0.97) 1.00 0.58 (0.23,1.43) 0.50 (0.12,2.06) 0.231
ESR2 38 bp 39 of STP G.A
G/G 1.00 0.84 (0.42,1.69) 1.00 0.79 (0.42,1.50) 1.33 (0.58,3.00) 0.654
G/A, A/A 1.00 0.87 (0.51,1.49) 1.00 0.64 (0.40,1.02) 0.43 (0.20,0.93) 0.015
ESR2 5659 bp 39 of STP A.G
G/G 1.00 0.95 (0.30,3.03) 1.00 0.98 (0.34,12.82) 2.22 (0.63,7.79) 0.269
G/A, A/A 1.00 0.78 (0.48,1.25) 1.00 0.65 (0.43,0.97) 0.63 (0.33,1.19) 0.054
ESR2 5696 bp 39 of STP A.G
A/A 1.00 1.08 (0.69,1.71) 1.00 0.72 (0.48,1.08) 0.83 (0.47,1.48) 0.310
A/G,G/G 1.00 0.20 (0.05,0.89) 1.00 0.56 (0.20,1.57) 0.44 (0.10,1.98) 0.227
ESR2 5772 bp 39 of STP A.G
A/A 1.00 0.83 (0.53,1.30) 1.00 0.66 (0.44,0.99) 0.73 (0.41,1.30) 0.125
A/G,G/G 1.00 0.47 (0.40,5.44) 1.00 0.71 (0.25,2.02) 0.83 (0.20,3.41) 0.703
*For phytoestrogen, additional adjustment for total energy intake was made; all odds ratios are adjusted for age and race.
{Low and High is defined as below and above the median total phytoestrogen intake of controls.
{NA: no applicable estimate due to small sample number.
doi:10.1371/journal.pone.0006523.t004
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proportion of missing data went up to around 30%. A high
proportion of missing data significantly decreases the sample size
available for statistical analysis, and consequently decreases
statistical power. However, in imputation analysis, inserting zero
or median in place of missing data did not affect the overall results.
Second, the amount of phytoestrogen consumed in the Washing-
ton County was much less than that in Southeast Asia where soy is
consumed habitually in moderate to large quantity. This may be
one of the reasons that explained the discrepancies found between
studies in Asia and the present study [21].
With regard to the test for interactive effects, the significance
level (type I error rate) is the probability of falsely reporting
significant interaction. Assuming the same effects across strata, the
probability of finding at least one significant interaction by chance
alone when undertaking 20 independent subgroup analyses such
as in table 4 is 65% [43]. When the corrected p value for over-
inflated false positive rate [44], 0.0025 (0.05420), is applied to
table 4, one interaction remains statistically significant: with ESR1
Ex1-192G.C (log likelihood ratio test: p=0.0009,0.0025),
suggesting that this SNP was a strong effect modifier on the
association between dietary intake of phytoestrogen and prostate
cancer risk.
A major limitation of this study is that only a subset of known
SNPs in two genes, ESR1 and ESR2, were examined:. Only 3 out
of 10 selected SNPs (ESR1 Ex1+392T.C, ESR2 Ex8+229G.A,
and ESR1 Ex4-122C.G) were studied in the past [28,42], where
null associations with prostate cancer risk were observed,
consistent with our study findings. However, for the other 7 SNPs
selected, our group was the first to report no overall association
between those SNPs and prostate cancer incidence.
Functions of all candidate SNPs remain unclear. All of the four
ESR1 SNPs in exons were synonymous polymorphisms with no
associated amino acid change. Therefore, it is unlikely that these
polymorphisms are causative. Yet, they may be in linkage
disequilibrium with an unknown causative variant. Or, they can
cause a structural change in RNA, altering translation efficacy,
and thereby, leading to a change in ESR1 gene expression rate
[22]. The situation is the same for other SNPs either in non-coding
regions or in introns, warranting further functional or expression
studies.
Tests of prostate-specific antigen (PSA) have been increasingly
used for screening and diagnosis of prostate cancer since early
1990s. Differential use of PSA test between cases and controls may
result in detection bias. In this study, there was no evidence of
over-diagnoses of early cancer using PSA tests and digital rectal
examinations (DRE) [44]. No appreciable difference in PSA test
rate between cases and controls was observed. We had few African
Americans and no Asians in the cohort, so we did not examine the
associations in various ethnic groups.
In summary, no overall statistically significant association
between prostate cancer risk and the selected ten SNPs in ESR1
and ESR2 genes was observed. However, four SNPs (rs2077647,
rs2273206, rs4986938, rs928554) may be linked with higher risk
for being diagnosed to have advanced stage disease. In addition,
there may be an interactive effect between BMI/phytoestrogen
and ESR genotypes on the risk of prostate cancer. Further
investigations are needed to see if the study is replicable in other
populations, especially in other ethnic groups, and to find out how
the gene-environment interaction can be explained under the
biological models.
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